ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Synthesis

Big Pharma On Repeat

November 2, 2015 | APPEARED IN VOLUME 93, ISSUE 43

One notices from the juicy Aug. 3 issue of C&EN that the big pharma broken record is still spinning mightily. Specifically, it appears that big pharma is, as usual, in Brownian motion mode. For example, A acquires B,C outsources its R&D, D and E contract with China or India to produce “stuff,” F slashes its chemistry staff, while the overpaid chief executive officer serves as the company mouthpiece, blah, blah, blah.

And to add insult to injury, A through F and myriad others are moving to Boston (page 13)! So, where, in the midst of all this churning, is a product such as a cure for cancer or a cure for diabetes or cystic fibrosis? Maybe the black hole for talent and money that is evolving in Massachusetts can cough up some results, maybe sometime?

Robert Pellenbarg
Palm Desert, Calif.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment